Description: We are a biotechnology company committed to addressing serious infectious diseases globally through the discovery and development of innovative vaccines.
Our vaccine technology leverages our proprietary recombinant protein-based nanoparticle technology and the immunogenicity-enhancing properties of our Matrix-M™ adjuvant.
Nanoparticles: By organizing recombinant proteins in a nanoparticle, it helps the immune system recognize that target protein from different angles 1 —the same way that the immune system would see the details of a real pathogen. In Novavax vaccines, there's no actual virus, just the protein; therefore, vaccines can't cause disease.
Matrix-M adjuvant: Our Matrix-M adjuvant comes from saponins, naturally occurring compounds in the bark of the Quillaja saponaria (Soapbark) tree, commonly found in Chile. Saponins have a long history of being used for their medicinal properties. 2 A vaccine containing another saponin-based adjuvant has previously been approved by the European Medicines Agency (EMA). 3
Eine neue Ära der Impfstoffentwicklung für Schweiz | Novavax
En ny epok för vacciner i Sverige | Novavax
Protein Based Vaccines | Novavax Germany
We never rest in our quest to protect the health of people everywhere | Novavax